{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T13:59:03Z","timestamp":1793627943398,"version":"4.5.1"},"reference-count":248,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","joms.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Oral and Maxillofacial Surgery"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.joms.2022.02.008","type":"journal-article","created":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:22:56Z","timestamp":1645471376000},"page":"920-943","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1125,"title":["American Association of Oral and Maxillofacial Surgeons\u2019 Position Paper on Medication-Related Osteonecrosis of the Jaws\u20142022 Update"],"prefix":"10.1016","volume":"80","author":[{"given":"Salvatore L.","family":"Ruggiero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas B.","family":"Dodson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Aghaloo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric R.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent B.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Kademani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.joms.2022.02.008_bib1","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws","volume":"65","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"issue":"Supp 1","key":"10.1016\/j.joms.2022.02.008_bib2","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaw - 2009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib3","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw\u20132014 update","volume":"72","author":"Ruggiero","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib4","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"Zoledronic acid prostate cancer study G. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.joms.2022.02.008_bib5","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1093\/annonc\/mdr435","article-title":"Incidence, risk factors, and outcomes of osteonecrosis of the jaw: Integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases","volume":"23","author":"Saad","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib6","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2003.04.105","article-title":"Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial\u2013the zoledronic acid lung cancer and other solid tumors study group","volume":"21","author":"Rosen","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib7","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.joms.2022.02.008_bib8","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib9","first-page":"488","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"Myeloma Aredia Study Group N Engl J Med"},{"key":"10.1016\/j.joms.2022.02.008_bib10","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib11","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/13696998.2019.1651122","article-title":"Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States","volume":"23","author":"Stopeck","year":"2020","journal-title":"J Med Econ"},{"key":"10.1016\/j.joms.2022.02.008_bib13","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s00774-019-01052-6","article-title":"Zoledronic acid and skeletal-related events in patients with bone metastatic cancer or multiple myeloma","volume":"38","author":"Jeon","year":"2020","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.joms.2022.02.008_bib14","first-page":"462","article-title":"The use of bisphosphonates in the treatment of osteoporosis","volume":"17","author":"Delmas","year":"2005","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.joms.2022.02.008_bib15","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0749-0690(02)00069-1","article-title":"Bisphosphonate treatment of osteoporosis","volume":"19","author":"Watts","year":"2003","journal-title":"Clin Geriatr Med"},{"key":"10.1016\/j.joms.2022.02.008_bib16","doi-asserted-by":"crossref","first-page":"115158","DOI":"10.1016\/j.bone.2019.115158","article-title":"The effect of bisphosphonates on bone turnover and bone balance in postmenopausal women with osteoporosis: The T-score bone marker approach in the TRIO study","volume":"131","author":"Gossiel","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.joms.2022.02.008_bib17","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.joms.2022.02.008_bib18","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.joms.2022.02.008_bib19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00198-016-3736-y","article-title":"Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: Two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in efficacy to osteoporosis; ZONE study)","volume":"28","author":"Nakamura","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.joms.2022.02.008_bib20","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1210\/er.2001-2002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. II. Meta-analysis of alendronate for the treatment of postmenopausal women","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr Rev"},{"key":"10.1016\/j.joms.2022.02.008_bib21","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1056\/NEJM199702203360807","article-title":"The management of Paget\u2019s disease of bone","volume":"336","author":"Delmas","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.joms.2022.02.008_bib22","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1359\/JBMR.050109","article-title":"Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement","volume":"20","author":"Letocha","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2022.02.008_bib23","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/jbmr.3649","article-title":"Age-related changes and effects of bisphosphonates on bone turnover and disease progression in fibrous dysplasia of bone","volume":"34","author":"Florenzano","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2022.02.008_bib24","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1210\/jc.2014-1371","article-title":"A randomized, double blind, placebo-controlled trial of alendronate treatment for fibrous dysplasia of bone","volume":"99","author":"Boyce","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.joms.2022.02.008_bib25","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.joms.2022.02.008_bib26","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1002\/jbmr.1479","article-title":"Five years of denosumab exposure in women with postmenopausal osteoporosis: Results from the first two years of the FREEDOM extension","volume":"27","author":"Papapoulos","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2022.02.008_bib27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00198-020-05699-0","article-title":"Combining fracture outcomes in phase 3 trials of osteoporosis: An analysis of the effects of denosumab in postmenopausal women","volume":"32","author":"Kanis","year":"2021","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.joms.2022.02.008_bib28","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00198-019-05233-x","article-title":"Efficacy and safety of denosumab vs. bisphosphonates in postmenopausal women previously treated with oral bisphosphonates","volume":"31","author":"Miller","year":"2020","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.joms.2022.02.008_bib29","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1182\/bloodadvances.2020002378","article-title":"Denosumab compared with zoledronic acid on PFS in multiple myeloma: Exploratory results of an international phase 3 study","volume":"5","author":"Terpos","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.joms.2022.02.008_bib30","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomized, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.joms.2022.02.008_bib31","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib32","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(13)70277-8","article-title":"Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: Interim analysis of an open-label, parallel-group, phase 2 study","volume":"14","author":"Chawla","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib33","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.joms.2017.09.013","article-title":"Denosumab as a treatment alternative for central giant cell granuloma: A long-term retrospective cohort study","volume":"76","author":"Bredell","year":"2018","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib34","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s11914-017-0380-1","article-title":"Denosumab: An emerging therapy in pediatric bone Disorders","volume":"15","author":"Boyce","year":"2017","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.joms.2022.02.008_bib35","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1002\/jbmr.3602","article-title":"Activation of RANK\/RANKL\/OPG pathway is involved in the pathophysiology of fibrous dysplasia and associated with disease burden","volume":"34","author":"de Castro","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2022.02.008_bib36","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1002\/jbmr.3828","article-title":"RANKL inhibition in fibrous dysplasia of bone: A preclinical study in a mouse model of the human disease","volume":"34","author":"Palmisano","year":"2019","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2022.02.008_bib37","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or alendronate for fracture prevention in women with osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.joms.2022.02.008_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17165998","article-title":"Medication-related osteonecrosis of jaws (MRONJ) prevention and diagnosis: Italian consensus update 2020","volume":"17","author":"Campisi","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.joms.2022.02.008_bib39","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1302\/0301-620X.77B1.7822393","article-title":"A quantitative system for staging avascular necrosis","volume":"77","author":"Steinberg","year":"1995","journal-title":"J Bone Joint Surg Br"},{"key":"10.1016\/j.joms.2022.02.008_bib40","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.tripleo.2010.04.023","article-title":"Predicting risk for bisphosphonate-related osteonecrosis of the jaws: CTX versus radiographic markers","volume":"110","author":"Fleisher","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.joms.2022.02.008_bib41","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.amjmed.2010.04.033","article-title":"Nonexposed variant of bisphosphonate-associated osteonecrosis of the jaw: A case series","volume":"123","author":"Fedele","year":"2010","journal-title":"Am J Med"},{"key":"10.1016\/j.joms.2022.02.008_bib42","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.oooo.2018.09.012","article-title":"Comorbid conditions are a risk for osteonecrosis of the jaw unrelated to antiresorptive therapy","volume":"127","author":"Fleisher","year":"2019","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.joms.2022.02.008_bib43","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1834-7819.2003.tb00011.x","article-title":"Oral ulceration with bone sequestration","volume":"48","author":"Farah","year":"2003","journal-title":"Aust Dent J"},{"key":"10.1016\/j.joms.2022.02.008_bib44","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/j.1600-0714.1997.tb00245.x","article-title":"Sequestration of the alveolar bone by invasive aspergillosis in acute myeloid leukemia","volume":"26","author":"Filippi","year":"1997","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.joms.2022.02.008_bib45","first-page":"366","article-title":"Bone sequestration from lower 3rd molar region","volume":"193","author":"Friel","year":"2002","journal-title":"Br Dent J"},{"key":"10.1016\/j.joms.2022.02.008_bib46","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.bjoms.2005.05.012","article-title":"Extensive maxillary sequestration resulting from mucormycosis","volume":"43","author":"Huang","year":"2005","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib47","first-page":"71","article-title":"American Academy of Oral and Maxillofacial Pathology. Persistent painful ulcer of the posterior lingual mandibular mucosa","volume":"4","author":"Peters","year":"2003","journal-title":"J Contemp Dent Pract"},{"key":"10.1016\/j.joms.2022.02.008_bib48","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1902\/jop.1997.68.8.758","article-title":"Spontaneous bony exposure: A report of 4 cases of idiopathic exposure and sequestration of alveolar bone","volume":"68","author":"Sonnier","year":"1997","journal-title":"J Periodontol"},{"key":"10.1016\/j.joms.2022.02.008_bib49","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/0030-4220(93)90433-5","article-title":"Lingual mandibular sequestration and ulceration","volume":"75","author":"Peters","year":"1993","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1016\/j.joms.2022.02.008_bib50","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0266-4356(90)90014-C","article-title":"Massive sequestration of the upper jaw: A case report","volume":"28","author":"Nandakumar","year":"1990","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib51","first-page":"989","article-title":"Extensive maxillary sequestration resulting from rhinocerebral mucormyocosis","volume":"35","author":"Ramon","year":"1977","journal-title":"J Oral Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib52","doi-asserted-by":"crossref","first-page":"e024655","DOI":"10.1136\/bmjopen-2018-024655","article-title":"Increased risk of bisphosphonate-related osteonecrosis of the jaw in patients with Sjogren\u2019s syndrome: Nationwide population-based cohort study","volume":"9","author":"Liao","year":"2019","journal-title":"BMJ Open"},{"key":"10.1016\/j.joms.2022.02.008_bib53","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/hed.2890040313","article-title":"Osteonecrosis of the jaws. A complication of cancer chemotherapy","volume":"4","author":"Schwartz","year":"1982","journal-title":"Head Neck Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib54","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/sj.bdj.4803994","article-title":"Tooth exfoliation and osteonecrosis of the jaw following herpes zoster","volume":"143","author":"Cooper","year":"1977","journal-title":"Br Dent J"},{"key":"10.1016\/j.joms.2022.02.008_bib55","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0300-9785(82)80060-4","article-title":"Tooth exfoliation, osteonecrosis of the jaw and neuralgia following herpes zoster of the trigeminal nerve","volume":"11","author":"Schwartz","year":"1982","journal-title":"Int J Oral Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib56","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1001\/archotol.1988.01860220091031","article-title":"Osteomyelitis of the mandible","volume":"114","author":"Calhoun","year":"1988","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib57","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0030-4220(92)90373-X","article-title":"Retrospective assessment of osteomyelitis. Etiology, demographics, risk factors, and management in 35 cases","volume":"74","author":"Koorbusch","year":"1992","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1016\/j.joms.2022.02.008_bib58","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00774-011-0331-3","article-title":"Children and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jaw","volume":"30","author":"Maines","year":"2012","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.joms.2022.02.008_bib59","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: The fracture intervention trial long-term extension (FLEX): A randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.joms.2022.02.008_bib60","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal fracture trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2022.02.008_bib61","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: A randomized second extension to the HORIZON-Pivotal fracture trial (PFT)","volume":"30","author":"Black","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2022.02.008_bib62","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/j.joms.2013.05.014","article-title":"Metastatic cancer identified in osteonecrosis specimens of the jaws in patients receiving intravenous bisphosphonate medications","volume":"71","author":"Carlson","year":"2013","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib63","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1016\/j.joms.2018.05.025","article-title":"Nonsurgical management of medication-related osteonecrosis of the jaws using local wound care","volume":"76","author":"Hadaya","year":"2018","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib64","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib65","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.coms.2015.06.001","article-title":"Pathophysiology of osteonecrosis of the jaws","volume":"27","author":"Aghaloo","year":"2015","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"10.1016\/j.joms.2022.02.008_bib66","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.mcna.2020.06.004","article-title":"Osteoporosis in older adults","volume":"104","author":"Johnston","year":"2020","journal-title":"Med Clin North Am"},{"key":"10.1016\/j.joms.2022.02.008_bib67","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","article-title":"Clinical practice","volume":"374","author":"Black","year":"2016","journal-title":"Postmenopausal Osteoporos N Engl J Med"},{"key":"10.1016\/j.joms.2022.02.008_bib68","first-page":"115735","article-title":"Pharmacologic management of metastatic bone disease","author":"Schwartz","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.joms.2022.02.008_bib69","doi-asserted-by":"crossref","first-page":"115570","DOI":"10.1016\/j.bone.2020.115570","article-title":"Bisphosphonates and breast cancer from cautious palliation to saving lives","volume":"140","author":"Coleman","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.joms.2022.02.008_bib70","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: Elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.joms.2022.02.008_bib71","doi-asserted-by":"crossref","first-page":"4925","DOI":"10.1200\/JCO.2005.06.091","article-title":"Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid","volume":"23","author":"Coleman","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib72","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1056\/NEJMcp042806","article-title":"Clinical practice. Hypercalcemia associated with cancer","volume":"352","author":"Stewart","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.joms.2022.02.008_bib73","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.afos.2016.03.003","article-title":"Review on the comparison of effectiveness between denosumab and bisphosphonates in post-menopausal osteoporosis","volume":"2","author":"Benjamin","year":"2016","journal-title":"Osteoporos Sarcopenia"},{"key":"10.1016\/j.joms.2022.02.008_bib74","first-page":"e326","article-title":"Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab vs.. zoledronic acid: A systematic review and meta-analysis","volume":"25","author":"Limones","year":"2020","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.joms.2022.02.008_bib75","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.oooo.2018.08.015","article-title":"Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw-a 4-year prospective study","volume":"126","author":"Hallmer","year":"2018","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.joms.2022.02.008_bib76","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.bone.2016.06.011","article-title":"Osteonecrosis of the jaws (ONJ) in mice after extraction of teeth with periradicular disease","volume":"90","author":"Soundia","year":"2016","journal-title":"Bone"},{"key":"10.1016\/j.joms.2022.02.008_bib77","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12967-019-1819-1","article-title":"Osteoclastic expression of higher-level regulators NFATc1 and BCL6 in medication-related osteonecrosis of the jaw secondary to bisphosphonate therapy: A comparison with osteoradionecrosis and osteomyelitis","volume":"17","author":"Wehrhan","year":"2019","journal-title":"J Transl Med"},{"key":"10.1016\/j.joms.2022.02.008_bib78","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1002\/jbmr.2490","article-title":"OPG-Fc but not zoledronic acid discontinuation reverses osteonecrosis of the jaws (ONJ) in mice","volume":"30","author":"de Molon","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2022.02.008_bib79","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1177\/0022034520986804","article-title":"Antiresorptive-type and discontinuation-timing Affect ONJ burden","volume":"100","author":"Hadaya","year":"2021","journal-title":"J Dent Res"},{"key":"10.1016\/j.joms.2022.02.008_bib80","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1007\/s00198-013-2570-8","article-title":"Early effects of parathyroid hormone on bisphosphonate\/steroid-associated compromised osseous wound healing","volume":"25","author":"Kuroshima","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.joms.2022.02.008_bib81","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.ijom.2013.05.001","article-title":"The effects of adjunctive parathyroid hormone injection on bisphosphonate-related osteonecrosis of the jaws: An animal study","volume":"42","author":"Dayisoylu","year":"2013","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib82","doi-asserted-by":"crossref","first-page":"e469","DOI":"10.1097\/MJT.0000000000001182","article-title":"Teriparatide for the treatment of medication-related osteonecrosis of the jaw","volume":"28","author":"Chopra","year":"2021","journal-title":"Am J Ther"},{"key":"10.1016\/j.joms.2022.02.008_bib83","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1600-051X.2005.00842.x","article-title":"Osteonecrosis of the jaws in periodontal patients with a history of bisphosphonates treatment","volume":"32","author":"Ficarra","year":"2005","journal-title":"J Clin Periodontol"},{"key":"10.1016\/j.joms.2022.02.008_bib84","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1902\/jop.2013.130017","article-title":"Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw","volume":"85","author":"Thumbigere-Math","year":"2014","journal-title":"J Periodontol"},{"key":"10.1016\/j.joms.2022.02.008_bib85","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/jbmr.379","article-title":"Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat","volume":"26","author":"Aghaloo","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2022.02.008_bib86","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1002\/jbmr.1894","article-title":"Periapical disease and bisphosphonates induce osteonecrosis of the jaws in mice","volume":"28","author":"Kang","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2022.02.008_bib87","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.joms.2018.08.010","article-title":"Development of medication-related osteonecrosis of the jaw after extraction of teeth with experimental periapical disease","volume":"77","author":"Hadaya","year":"2019","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib88","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1002\/jbmr.1669","article-title":"Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis","volume":"27","author":"Aguirre","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2022.02.008_bib89","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s00774-020-01174-2","article-title":"Tooth extraction in mice administered zoledronate increases inflammatory cytokine levels and promotes osteonecrosis of the jaw","volume":"39","author":"Soma","year":"2021","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.joms.2022.02.008_bib90","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1002\/jbmr.2827","article-title":"Rheumatoid arthritis Exacerbates the severity of osteonecrosis of the jaws (ONJ) in mice. A randomized, prospective, controlled animal study","volume":"31","author":"de Molon","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2022.02.008_bib91","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1016\/j.ajpath.2018.06.019","article-title":"Removal of pre-existing periodontal inflammatory condition before tooth extraction Ameliorates medication-related osteonecrosis of the jaw-like lesion in mice","volume":"188","author":"Kim","year":"2018","journal-title":"Am J Pathol"},{"key":"10.1016\/j.joms.2022.02.008_bib92","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s13287-019-1308-8","article-title":"Systemic administration of quality and quantity-controlled PBMNCs reduces bisphosphonate-related osteonecrosis of jaw-like lesions in mice","volume":"10","author":"Kuroshima","year":"2019","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.joms.2022.02.008_bib93","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1600-0714.2006.00391.x","article-title":"Osteonecrosis of the jaws in patients treated with bisphosphonates histomorphologic analysis in comparison with infected osteoradionecrosis","volume":"35","author":"Hansen","year":"2006","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.joms.2022.02.008_bib94","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1177\/0022034511420430","article-title":"A role of oral bacteria in bisphosphonate-induced osteonecrosis of the jaw","volume":"90","author":"Mawardi","year":"2011","journal-title":"J Dent Res"},{"key":"10.1016\/j.joms.2022.02.008_bib95","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1093\/annonc\/mdr039","article-title":"Impact of dental care in the prevention of bisphosphonate-associated osteonecrosis of the jaw: A single-center clinical experience","volume":"23","author":"Vandone","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib96","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.14219\/jada.archive.2009.0049","article-title":"Microbial biofilms in osteomyelitis of the jaw and osteonecrosis of the jaw secondary to bisphosphonate therapy","volume":"140","author":"Sedghizadeh","year":"2009","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.joms.2022.02.008_bib97","doi-asserted-by":"crossref","first-page":"506","DOI":"10.14219\/jada.archive.2011.0220","article-title":"Osteonecrosis of the jaw in patients with cancer who received zoledronic acid and bevacizumab","volume":"142","author":"Francini","year":"2011","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.joms.2022.02.008_bib98","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21130","article-title":"Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy","volume":"104","author":"Migliorati","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.joms.2022.02.008_bib99","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1302\/2058-5241.4.180036","article-title":"Osteonecrosis of the femoral head: Pathophysiology and current concepts of treatment","volume":"4","author":"Petek","year":"2019","journal-title":"EFORT Open Rev"},{"key":"10.1016\/j.joms.2022.02.008_bib100","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1124\/jpet.102.035295","article-title":"Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid","volume":"302","author":"Wood","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.joms.2022.02.008_bib101","first-page":"2893","article-title":"Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients","volume":"9","author":"Santini","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.joms.2022.02.008_bib102","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.cyto.2014.10.025","article-title":"The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells","volume":"71","author":"Ishtiaq","year":"2015","journal-title":"Cytokine"},{"key":"10.1016\/j.joms.2022.02.008_bib103","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1007\/s00784-018-2385-2","article-title":"Bone mineralization and vascularization in bisphosphonate-related osteonecrosis of the jaw: An experimental study in the rat","volume":"22","author":"Kun-Darbois","year":"2018","journal-title":"Clin Oral Investig"},{"key":"10.1016\/j.joms.2022.02.008_bib104","doi-asserted-by":"crossref","first-page":"115117","DOI":"10.1016\/j.bone.2019.115117","article-title":"PDGF-BB exhibited therapeutic effects on rat model of bisphosphonate-related osteonecrosis of the jaw by enhancing angiogenesis and osteogenesis","volume":"144","author":"Gao","year":"2021","journal-title":"Bone"},{"key":"10.1016\/j.joms.2022.02.008_bib105","doi-asserted-by":"crossref","first-page":"280","DOI":"10.2353\/ajpath.2010.090592","article-title":"Bisphosphonates cause osteonecrosis of the jaw-like disease in mice","volume":"177","author":"Bi","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.joms.2022.02.008_bib106","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.bone.2019.03.031","article-title":"Vasculature submucosal changes at early stages of osteonecrosis of the jaw (ONJ)","volume":"123","author":"Gkouveris","year":"2019","journal-title":"Bone"},{"key":"10.1016\/j.joms.2022.02.008_bib107","doi-asserted-by":"crossref","first-page":"e326","DOI":"10.4317\/medoral.22858","article-title":"Osteonecrosis of the jaws produced by sunitinib: A systematic review","volume":"24","author":"Vallina","year":"2019","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"1","key":"10.1016\/j.joms.2022.02.008_bib108","first-page":"161","article-title":"Angiogenic factors as potential drug target: Efficacy and limitations of anti-angiogenic therapy","volume":"1846","author":"Gacche","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.joms.2022.02.008_bib109","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s00774-017-0872-1","article-title":"Effect of anti-angiogenesis induced by chemotherapeutic monotherapy, chemotherapeutic\/bisphosphonate combination therapy and anti-VEGFA mAb therapy on tooth extraction socket healing in mice","volume":"36","author":"Akita","year":"2018","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.joms.2022.02.008_bib110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3390\/dj4040032","article-title":"Prevalence of medication-related osteonecrosis of the jaw in patients with breast cancer, prostate cancer, and multiple myeloma","volume":"4","author":"Rugani","year":"2016","journal-title":"Dent J (Basel)"},{"key":"10.1016\/j.joms.2022.02.008_bib111","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.joms.2022.02.008_bib112","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1200\/JCO.2005.04.2465","article-title":"Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors","volume":"24","author":"Badros","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib113","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S1470-2045(18)30072-X","article-title":"Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: An international, double-blind, double-dummy, randomised, controlled, phase 3 study","volume":"19","author":"Raje","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib114","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1007\/s00432-010-0907-7","article-title":"Bisphosphonate-induced osteonecrosis of the jaw: A review of 2,400 patient cases","volume":"136","author":"Filleul","year":"2010","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib115","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/sj.bdj.2017.888","article-title":"In-vivo imaging of the microvasculature of the soft tissue margins of osteonecrotic jaw lesions","volume":"223","author":"Bastos","year":"2017","journal-title":"Br Dent J"},{"key":"10.1016\/j.joms.2022.02.008_bib116","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1002\/jbmr.2577","article-title":"Bisphosphonate induces osteonecrosis of the jaw in diabetic mice via NLRP3\/Caspase-1Dependent IL-1 beta mechanism","volume":"30","author":"Zhang","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2022.02.008_bib117","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1186\/1471-2407-14-338","article-title":"Immunotherapy of hepatocellular carcinoma with small double-stranded RNA","volume":"14","author":"Kabilova","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.joms.2022.02.008_bib118","doi-asserted-by":"crossref","first-page":"115308","DOI":"10.1016\/j.bone.2020.115308","article-title":"Distinct immunopathology in the early stages between different antiresorptives-related osteonecrosis of the jaw-like lesions in mice","volume":"135","author":"Hayano","year":"2020","journal-title":"Bone"},{"key":"10.1016\/j.joms.2022.02.008_bib119","doi-asserted-by":"crossref","first-page":"1271492","DOI":"10.1155\/2019\/1271492","article-title":"Effect of periapical diseases in development of MRONJ in immunocompromised mouse model","volume":"2019","author":"Rao","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.joms.2022.02.008_bib120","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.joms.2016.07.019","article-title":"Osteonecrosis of the jaw in the absence of antiresorptive or antiangiogenic exposure: A series of 6 cases","volume":"75","author":"Aghaloo","year":"2017","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib121","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib122","doi-asserted-by":"crossref","first-page":"20743","DOI":"10.18632\/aging.104006","article-title":"Determination of the molecular mechanism by which macrophages and gammadelta-T cells contribute to ZOL-induced ONJ","volume":"12","author":"Qu","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.joms.2022.02.008_bib123","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.3390\/jcm9061649","article-title":"Allogeneic bone marrow mesenchymal stem cell transplantation in tooth extractions sites Ameliorates the incidence of osteonecrotic jaw-like lesions in zoledronic acid-treated rats","volume":"9","author":"Rodriguez-Lozano","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.joms.2022.02.008_bib124","first-page":"e529","article-title":"Bisphosphonate-related osteonecrosis. Application of adipose-derived stem cells in an experimental murine model","volume":"24","author":"Alonso-Rodriguez","year":"2019","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.joms.2022.02.008_bib125","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jcms.2015.04.026","article-title":"Adipose-derived stem cells and platelet-rich plasma for preventive treatment of bisphosphonate-related osteonecrosis of the jaw in a murine model","volume":"43","author":"Barba-Recreo","year":"2015","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib126","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1182\/blood-2008-04-147884","article-title":"Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: A genome-wide single nucleotide polymorphism analysis","volume":"112","author":"Sarasquete","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.joms.2022.02.008_bib127","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/jbmr.3285","article-title":"SIRT1\/HERC4 Locus associated with bisphosphonate-induced osteonecrosis of the jaw: An Exome-wide association analysis","volume":"33","author":"Yang","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2022.02.008_bib128","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/jbmr.4185","article-title":"SIRT1 gene SNP rs932658 is associated with medication-related osteonecrosis of the jaw","volume":"36","author":"Yang","year":"2021","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2022.02.008_bib129","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1186\/s12967-019-2129-3","article-title":"Identifying genetic variants underlying medication-induced osteonecrosis of the jaw in cancer and osteoporosis: A case control study","volume":"17","author":"Lee","year":"2019","journal-title":"J Transl Med"},{"key":"10.1016\/j.joms.2022.02.008_bib130","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1080\/10428194.2017.1300889","article-title":"Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy","volume":"58","author":"Kastritis","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.joms.2022.02.008_bib131","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ijom.2019.07.016","article-title":"Pharmacogenetics of medication-related osteonecrosis of the jaw: A systematic review and meta-analysis","volume":"49","author":"Guo","year":"2020","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib132","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1634\/theoncologist.2012-0261","article-title":"Adjuvant therapy with zoledronic acid in patients with breast cancer: A systematic review and meta-analysis","volume":"18","author":"Valachis","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.joms.2022.02.008_bib133","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","article-title":"Adjuvant zoledronic acid in patients with early breast cancer: Final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial","volume":"15","author":"Coleman","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib134","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/S0140-6736(15)60995-3","article-title":"Adjuvant denosumab in breast cancer (ABCSG-18): A multicentre, randomised, double blind, placebo-controlled trial","volume":"386","author":"Gnant","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.joms.2022.02.008_bib135","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/clr.12556","article-title":"Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials","volume":"27","author":"Boquete-Castro","year":"2016","journal-title":"Clin Oral Implants Res"},{"key":"10.1016\/j.joms.2022.02.008_bib136","first-page":"CD006250","article-title":"Bisphosphonates for advanced prostate cancer","volume":"12","author":"Macherey","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.joms.2022.02.008_bib137","first-page":"CD003474","article-title":"Bisphosphonates and other bone agents for breast cancer","volume":"10","author":"O\u2019Carrigan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.joms.2022.02.008_bib138","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","article-title":"Adjuvant denosumab in early breast cancer (D-CARE): An international, multicentre, randomised, controlled, phase 3 trial","volume":"21","author":"Coleman","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib139","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/S1470-2045(13)70539-4","article-title":"Oral ibandronic acid versus intravenous zoledronic acid in treatment of bone metastases from breast cancer: A randomised, open label, noninferiority phase 3 trial","volume":"15","author":"Barrett-Lee","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib140","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2016.19425","article-title":"Effect of longer-Interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: A randomized clinical trial","volume":"317","author":"Himelstein","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.joms.2022.02.008_bib141","first-page":"679","article-title":"Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: An analysis of data from patients with solid tumors","volume":"22","author":"Henry","year":"2014","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.joms.2022.02.008_bib142","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ctrv.2012.07.002","article-title":"Denosumab in patients with cancer and skeletal metastases: A systematic review and meta-analysis","volume":"39","author":"Peddi","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.joms.2022.02.008_bib143","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/bjh.12861","article-title":"Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results","volume":"166","author":"Jackson","year":"2014","journal-title":"Br J Haematol"},{"key":"10.1016\/j.joms.2022.02.008_bib144","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.3892\/ol.2014.1982","article-title":"Comparison of the efficacy and safety of denosumab versus bisphosphonates in breast cancer and bone metastases treatment: A meta-analysis of randomized controlled trials","volume":"7","author":"Wang","year":"2014","journal-title":"Oncol Lett"},{"key":"10.1016\/j.joms.2022.02.008_bib145","first-page":"925","article-title":"Long-term impact of bone-modifying agents for the treatment of bone metastases: A systematic review","volume":"29","author":"Ng","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.joms.2022.02.008_bib146","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1080\/14740338.2016.1177021","article-title":"Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: New horizons in oncology","volume":"15","author":"Fusco","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.joms.2022.02.008_bib147","first-page":"383","article-title":"Osteonecrosis of the jaw related to non-antiresorptive medications: A systematic review","volume":"27","author":"Nicolatou-Galitis","year":"2019","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.joms.2022.02.008_bib148","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.oooo.2018.11.012","article-title":"Medication-related osteonecrosis of the jaw unrelated to bisphosphonates and denosumab-a review","volume":"127","author":"King","year":"2019","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.joms.2022.02.008_bib149","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bjoms.2019.09.023","article-title":"Osteonecrosis and osteomyelitis of the jaw associated with tumour necrosis factor-alpha (TNF-alpha) inhibitors: A systematic review","volume":"58","author":"Sacco","year":"2020","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib150","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.14219\/jada.archive.2010.0082","article-title":"The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: Data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program","volume":"141","author":"Grbic","year":"2010","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.joms.2022.02.008_bib151","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.joms.2022.02.008_bib152","series-title":"Background Document for Meeting of Advisory Committee for Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee","year":"2011"},{"key":"10.1016\/j.joms.2022.02.008_bib153","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","article-title":"10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension","volume":"5","author":"Bone","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.joms.2022.02.008_bib154","series-title":"Briefing Information for the September 9, 2011 Joint Meeting of the Reproductive Health Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee","year":"2011"},{"key":"10.1016\/j.joms.2022.02.008_bib155","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.ejso.2018.03.020","article-title":"Denosumab treatment of inoperable or locally advanced giant cell tumor of bone multicenter analysis outside clinical trial","volume":"44","author":"Rutkowski","year":"2018","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib156","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/S1470-2045(19)30663-1","article-title":"Denosumab in patients with giant-cell tumour of bone: A multicentre, open-label, phase 2 study","volume":"20","author":"Chawla","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib157","first-page":"e1","article-title":"Systematic review on the incidence of bisphosphonate related osteonecrosis of the jaw in children diagnosed with osteogenesis imperfecta","volume":"4","author":"Hennedige","year":"2013","journal-title":"J Oral Maxillofac Res"},{"key":"10.1016\/j.joms.2022.02.008_bib158","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijom.2019.08.004","article-title":"Can children be affected by bisphosphonate-related osteonecrosis of the jaw? A systematic review","volume":"49","author":"Duarte","year":"2020","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib159","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.joms.2009.03.050","article-title":"Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure","volume":"68","author":"Lo","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib160","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jcms.2017.05.028","article-title":"What is the effect of anti-resorptive drugs (ARDs) on the development of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: A systematic review","volume":"45","author":"Aljohani","year":"2017","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib161","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1007\/s00198-018-4621-7","article-title":"Long-term oral bisphosphonates delay healing after tooth extraction: A single institutional prospective study","volume":"29","author":"Shudo","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.joms.2022.02.008_bib162","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/jcpe.12455","article-title":"Occurrence and risk indicators of medication-related osteonecrosis of the jaw after dental extraction: A systematic review and meta-analysis","volume":"42","author":"Gaudin","year":"2015","journal-title":"J Clin Periodontol"},{"key":"10.1016\/j.joms.2022.02.008_bib163","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1210\/jc.2018-01965","article-title":"Invasive oral procedures and events in postmenopausal women with osteoporosis treated with denosumab for up to 10 Years","volume":"104","author":"Watts","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.joms.2022.02.008_bib164","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.oraloncology.2012.03.009","article-title":"Tooth extraction in patients on zoledronic acid therapy","volume":"48","author":"Mozzati","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib165","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.ijom.2012.06.020","article-title":"Increased incidence of osteonecrosis of the jaw after tooth extraction in patients treated with bisphosphonates: A cohort study","volume":"41","author":"Yamazaki","year":"2012","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib166","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.joms.2013.01.006","article-title":"Tooth extractions in intravenous bisphosphonate-treated patients: A refined protocol","volume":"71","author":"Scoletta","year":"2013","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib167","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jcms.2015.02.018","article-title":"Incidence of bisphosphonate-related osteonecrosis of the jaw in high-risk patients undergoing surgical tooth extraction","volume":"43","author":"Bodem","year":"2015","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib168","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/odi.12708","article-title":"Risk factors for medication-related osteonecrosis of the jaws: A systematic review","volume":"24","author":"McGowan","year":"2018","journal-title":"Oral Dis"},{"key":"10.1016\/j.joms.2022.02.008_bib169","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2008.16.2768","article-title":"Bisphosphonate-related osteonecrosis of the jaws: A case-control study of risk\u00a0factors in breast cancer patients","volume":"26","author":"Kyrgidis","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib170","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw","volume":"27","author":"Vahtsevanos","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib171","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1016\/j.joms.2013.02.016","article-title":"Oral health risk factors for bisphosphonate-associated jaw osteonecrosis","volume":"71","author":"Tsao","year":"2013","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib172","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10147-013-0561-6","article-title":"Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: A meta-analysis of seven randomized controlled trials","volume":"19","author":"Qi","year":"2014","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib173","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/mdn526","article-title":"Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan","volume":"20","author":"Ripamonti","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib174","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1080\/10428190802483778","article-title":"Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates","volume":"49","author":"Montefusco","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.joms.2022.02.008_bib175","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/030089161109700411","article-title":"Bisphosphonate-induced osteonecrosis of the jaw in patients with bone metastatic, hormone-sensitive prostate cancer. Risk factors and prevention strategies","volume":"97","author":"Bantis","year":"2011","journal-title":"Tumori"},{"key":"10.1016\/j.joms.2022.02.008_bib176","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1834-7819.2008.00078.x","article-title":"The oral health status of patients on oral bisphosphonates for osteoporosis","volume":"53","author":"Kunchur","year":"2008","journal-title":"Aust Dent J"},{"key":"10.1016\/j.joms.2022.02.008_bib177","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.joms.2009.07.068","article-title":"Tooth extraction in patients taking intravenous bisphosphonates: A preventive protocol and case series","volume":"68","author":"Lodi","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib178","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.oraloncology.2011.12.004","article-title":"Platelet-rich therapies in the treatment of intravenous bisphosphonate-related osteonecrosis of the jaw: A report of 32 cases","volume":"48","author":"Mozzati","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib179","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.joms.2010.10.055","article-title":"Preventive protocol for tooth extractions in patients treated with zoledronate: A case series","volume":"69","author":"Ferlito","year":"2011","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib180","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.oraloncology.2011.11.004","article-title":"The saxon bisphosphonate register - therapy and prevention of bisphosphonate-related osteonecrosis of the jaws","volume":"48","author":"Schubert","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib181","first-page":"b147","article-title":"Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: A review of 282 patients","volume":"77","author":"Bonacina","year":"2011","journal-title":"J Can Dent Assoc"},{"key":"10.1016\/j.joms.2022.02.008_bib182","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"International Task Force on Osteonecrosis of the Jaw. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2022.02.008_bib183","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s00774-016-0810-7","article-title":"Antiresorptive agent-related osteonecrosis of the jaw: Position paper 2017 of the Japanese Allied Committee on osteonecrosis of the jaw","volume":"35","author":"Yoneda","year":"2017","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.joms.2022.02.008_bib184","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jebdp.2017.11.002","article-title":"Recommendations for the prevention of bisphosphonate-related osteonecrosis of the jaw: A systematic review","volume":"18","author":"Aparecida Cariolatto","year":"2018","journal-title":"J Evid Based Dent Pract"},{"key":"10.1016\/j.joms.2022.02.008_bib185","first-page":"CD012432","article-title":"Interventions for managing medication-related osteonecrosis of the jaw","volume":"10","author":"Beth-Tasdogan","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.joms.2022.02.008_bib186","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.jcms.2016.07.026","article-title":"Prevention of bisphosphonate-related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid - a prospective study over 6 years","volume":"44","author":"Mucke","year":"2016","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib187","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.joms.2013.03.019","article-title":"Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma","volume":"71","author":"Smidt-Hansen","year":"2013","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib188","first-page":"1793","article-title":"Denosumab and anti-angiogenetic drug-related osteonecrosis of the jaw: An uncommon but potentially severe disease","volume":"33","author":"Sivolella","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.joms.2022.02.008_bib189","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.bjoms.2010.05.007","article-title":"Bisphosphonate osteonecrosis of the jaw\u2013a literature review of UK policies versus international policies on bisphosphonates, risk factors and prevention","volume":"49","author":"Patel","year":"2011","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib190","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: Executive summary of recommendations from the American Dental Association Council on scientific Affairs","volume":"142","author":"Hellstein","year":"2011","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.joms.2022.02.008_bib191","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s10103-011-0974-2","article-title":"Bisphosphonate-related osteonecrosis: Laser-assisted surgical treatment or conventional surgery?","volume":"26","author":"Atalay","year":"2011","journal-title":"Lasers Med Sci"},{"key":"10.1016\/j.joms.2022.02.008_bib192","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-010-0866-3","article-title":"Bevacizumab and osteonecrosis of the jaw: Incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer","volume":"122","author":"Guarneri","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.joms.2022.02.008_bib193","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.14219\/jada.archive.2008.0110","volume":"139","author":"Edwards","year":"2008","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.joms.2022.02.008_bib194","first-page":"e644","article-title":"Bisphosphonate treatment and dental implants: A systematic review","volume":"21","author":"de-Freitas","year":"2016","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.joms.2022.02.008_bib195","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2014.07.027","article-title":"Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: A novel ONJ mouse model","volume":"68","author":"de Molon","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.joms.2022.02.008_bib196","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1111\/odi.13052","article-title":"Zoledronate treatment duration is linked to bisphosphonate-related osteonecrosis of the jaw prevalence in rice rats with generalized periodontitis","volume":"25","author":"Messer","year":"2019","journal-title":"Oral Dis"},{"key":"10.1016\/j.joms.2022.02.008_bib197","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.oraloncology.2013.06.008","article-title":"Osteonecrosis of the jaw - prevention and treatment strategies for oral health professionals","volume":"49","author":"Hinchy","year":"2013","journal-title":"Oral Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib198","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","article-title":"International task Force on osteonecrosis of the Jaw: Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task Force on ONJ","volume":"20","author":"Khan","year":"2017","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.joms.2022.02.008_bib199","doi-asserted-by":"crossref","first-page":"e03795","DOI":"10.1016\/j.heliyon.2020.e03795","article-title":"Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review","volume":"6","author":"Ottesen","year":"2020","journal-title":"Heliyon"},{"key":"10.1016\/j.joms.2022.02.008_bib200","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/jbmr.3110","article-title":"Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: Systematic review and additional cases","volume":"32","author":"Anastasilakis","year":"2017","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2022.02.008_bib201","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/jbmr.3337","article-title":"Vertebral fractures after discontinuation of denosumab: A post Hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension","volume":"33","author":"Cummings","year":"2018","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2022.02.008_bib202","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.bone.2017.08.003","article-title":"Discontinuation of denosumab therapy for osteoporosis: A systematic review and position statement by ECTS","volume":"105","author":"Tsourdi","year":"2017","journal-title":"Bone"},{"key":"10.1016\/j.joms.2022.02.008_bib203","first-page":"e26","article-title":"Biomarkers to predict the onset of biphosphonate-related osteonecrosis of the jaw: A systematic review","volume":"24","author":"Lorenzo-Pouso","year":"2019","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.joms.2022.02.008_bib204","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s00277-018-3296-7","article-title":"Altered microRNA expression profile in the peripheral lymphoid compartment of multiple myeloma patients with bisphosphonate-induced osteonecrosis of the jaw","volume":"97","author":"Musolino","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.joms.2022.02.008_bib205","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.7150\/ijms.27593","article-title":"Circulating microRNA Panel as a novel biomarker to Diagnose bisphosphonate-related osteonecrosis of the jaw","volume":"15","author":"Yang","year":"2018","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.joms.2022.02.008_bib206","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1056\/NEJM200507073530120","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Durie","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.joms.2022.02.008_bib207","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1359\/jbmr.080205","article-title":"Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates","volume":"23","author":"Hoff","year":"2008","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2022.02.008_bib208","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib209","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1200\/JCO.19.01186","article-title":"Medication-related osteonecrosis of the jaw: MASCC\/ISOO\/ASCO clinical practice guideline","volume":"37","author":"Yarom","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib210","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00198-017-4345-0","article-title":"Hip fracture trends in the United States, 2002 to 2015","volume":"29","author":"Lewiecki","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.joms.2022.02.008_bib211","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s13018-019-1226-6","article-title":"Mortality after osteoporotic hip fracture: Incidence, trends, and associated factors","volume":"14","author":"Guzon-Illescas","year":"2019","journal-title":"J Orthop Surg Res"},{"key":"10.1016\/j.joms.2022.02.008_bib212","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.adaj.2020.01.021","article-title":"Clinical recommendations for prevention of secondary fractures in patients with osteoporosis: Implications for dental care","volume":"151","author":"McCauley","year":"2020","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.joms.2022.02.008_bib213","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/iej.12018","article-title":"Bisphosphonates and their clinical implications in endodontic therapy","volume":"46","author":"Moinzadeh","year":"2013","journal-title":"Int Endod J"},{"key":"10.1016\/j.joms.2022.02.008_bib214","first-page":"e2","article-title":"Dental implant placement in patients on bisphosphonate therapy: A systematic review","volume":"9","author":"Gelazius","year":"2018","journal-title":"J Oral Maxillofac Res"},{"key":"10.1016\/j.joms.2022.02.008_bib215","doi-asserted-by":"crossref","first-page":"1937.e1","DOI":"10.1016\/j.joms.2014.04.037","article-title":"Effect of dental implants on bisphosphonate-related osteonecrosis of the jaws","volume":"72","author":"Holzinger","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib216","first-page":"e195","article-title":"Medication-related osteonecrosis of the jaw associated with implant and regenerative treatments: Systematic review","volume":"24","author":"Granate-Marques","year":"2019","journal-title":"Med Oral Patol Oral Cir Bucal"},{"issue":"29 Suppl","key":"10.1016\/j.joms.2022.02.008_bib217","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/clr.13282","article-title":"The effect of antiresorptive drugs on implant therapy: Systematic review and meta-analysis","volume":"18","author":"Stavropoulos","year":"2018","journal-title":"B Clin Oral Implants Res"},{"key":"10.1016\/j.joms.2022.02.008_bib218","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/clr.13713","article-title":"Is implant surgery a risk factor for osteonecrosis of the jaw in older adult patients with osteoporosis? A national cohort propensity score-matched study","volume":"32","author":"Ryu","year":"2021","journal-title":"Clin Oral Implants Res"},{"key":"10.1016\/j.joms.2022.02.008_bib219","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/SCS.0000000000002564","article-title":"Medication-related osteonecrosis of the jaw around dental implants: Implant surgery-triggered or implant presence-triggered osteonecrosis?","volume":"27","author":"Giovannacci","year":"2016","journal-title":"J Craniofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib220","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/clr.12088","article-title":"Osteonecrosis associated with dental implants in patients undergoing bisphosphonate treatment","volume":"25","author":"Kwon","year":"2014","journal-title":"Clin Oral Implants Res"},{"key":"10.1016\/j.joms.2022.02.008_bib221","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ijom.2017.07.012","article-title":"Previously successful dental implants can fail when patients commence anti-resorptive therapy-a case series","volume":"47","author":"Pogrel","year":"2018","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib222","doi-asserted-by":"crossref","first-page":"20180128","DOI":"10.1259\/dmfr.20180128","article-title":"Medication related osteonecrosis of the jaw in osteoporotic vs oncologic patients - quantifying radiographic appearance and relationship to clinical findings","volume":"48","author":"Walton","year":"2019","journal-title":"Dentomaxillofac Radiol"},{"key":"10.1016\/j.joms.2022.02.008_bib223","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.bjoms.2017.06.014","article-title":"Medication-related osteonecrosis of the jaw in oncological patients with skeletal metastases: Conservative treatment is effective up to stage 2","volume":"55","author":"Coropciuc","year":"2017","journal-title":"Br J Oral Maxillofac Surg"},{"issue":"6","key":"10.1016\/j.joms.2022.02.008_bib224","article-title":"Radiographic predictors of bone exposure in patients with stage 0 medication-related osteonecrosis of the jaws","volume":"126","author":"Soundia","year":"2018","journal-title":"Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.joms.2022.02.008_bib225","article-title":"Conservative management of medication-related osteonecrosis of the jaws (MRONJ): A retrospective cohort study","volume":"10","author":"Varoni","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.joms.2022.02.008_bib226","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.oraloncology.2011.01.002","article-title":"Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase I-II study","volume":"47","author":"Ripamonti","year":"2011","journal-title":"Oral Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib227","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.joms.2012.04.001","article-title":"What is the role of hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis of the jaw: A randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics","volume":"70","author":"Freiberger","year":"2012","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib228","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.tripleo.2010.05.067","article-title":"Management of bisphosphonate-associated osteonecrosis: Pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series","volume":"110","author":"Epstein","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.joms.2022.02.008_bib229","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jos.2020.01.012","article-title":"Treatment outcomes of adjunctive teriparatide therapy for medication-related osteonecrosis of the jaw (MRONJ): A multicenter retrospective analysis in Japan","volume":"25","author":"Morishita","year":"2020","journal-title":"J Orthop Sci"},{"key":"10.1016\/j.joms.2022.02.008_bib230","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1200\/JCO.19.02192","article-title":"Teriparatide promotes bone healing in medication-related osteonecrosis of the jaw: A placebo-controlled, randomized trial","volume":"38","author":"Sim","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib231","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.joms.2009.01.006","article-title":"The role of surgical resection in the management of bisphosphonate-related osteonecrosis of the jaws","volume":"67","author":"Carlson","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib232","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jcms.2007.06.008","article-title":"\u201cBisphossy jaws\u201d - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw","volume":"36","author":"Abu-Id","year":"2008","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib233","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/hed.20864","article-title":"Treatment results of bisphosphonate-related osteonecrosis of the jaws","volume":"30","author":"Wutzl","year":"2008","journal-title":"Head Neck"},{"key":"10.1016\/j.joms.2022.02.008_bib234","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.joms.2008.12.057","article-title":"Outcome of surgical management of bisphosphonate-related osteonecrosis of the jaws: Review of 33 surgical cases","volume":"67","author":"Stanton","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib235","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.tripleo.2010.04.015","article-title":"The role of surgical therapy in the management of intravenous bisphosphonates-related osteonecrosis of the jaw","volume":"111","author":"Wilde","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.joms.2022.02.008_bib236","doi-asserted-by":"crossref","first-page":"971","DOI":"10.14219\/jada.archive.2007.0294","article-title":"The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors","volume":"138","author":"Adornato","year":"2007","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.joms.2022.02.008_bib237","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ijom.2009.11.014","article-title":"Surgical management of bisphosphonate induced osteonecrosis of the jaws","volume":"39","author":"Williamson","year":"2010","journal-title":"Int J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib238","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.joms.2013.12.007","article-title":"Management of antiresorptive osteonecrosis of the jaws with primary surgical resection","volume":"72","author":"Carlson","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib239","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.oooo.2012.05.017","article-title":"Intravenous bisphosphonate-related osteonecrosis of the jaw: Long-term follow-up of 109 patients","volume":"115","author":"Watters","year":"2013","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.joms.2022.02.008_bib240","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.jcms.2018.12.014","article-title":"Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study","volume":"47","author":"Ristow","year":"2019","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib241","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.coms.2014.01.005","article-title":"Anti-resorptive osteonecrosis of the jaws. Facts forgotten, questions answered, lessons learned","volume":"26","author":"Carlson","year":"2014","journal-title":"Oral Maxillofac Surg Clin North Am"},{"key":"10.1016\/j.joms.2022.02.008_bib242","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.jcms.2016.08.001","article-title":"Evaluation of surgical outcome and influencing risk factors in patients with medication-related osteonecrosis of the jaws","volume":"44","author":"Klingelhoffer","year":"2016","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib243","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.bjoms.2016.06.015","article-title":"Conservative surgical management of patients with bisphosphonate-related osteonecrosis of the jaws: A series of 120 patients","volume":"54","author":"Nisi","year":"2016","journal-title":"Br J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib244","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.suc.2010.08.001","article-title":"Complex wounds and their management","volume":"90","author":"Park","year":"2010","journal-title":"Surg Clin North Am"},{"key":"10.1016\/j.joms.2022.02.008_bib245","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1016\/j.joms.2020.05.037","article-title":"Can surgical management improve resolution of medication-related osteonecrosis of the jaw at early stages? A prospective cohort study","volume":"78","author":"Giudice","year":"2020","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2022.02.008_bib246","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/jbmr.4391","article-title":"Individualized bone-protective management in long-term cancer survivors with bone metastases","volume":"36","author":"Rachner","year":"2021","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2022.02.008_bib247","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdu544","volume":"26","author":"Gnant","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.joms.2022.02.008_bib248","first-page":"11","article-title":"The incidence and relative risk of adverse events in patients treated with bisphosphonate therapy for breast cancer: A systematic review and meta-analysis","volume":"9","author":"Yang","year":"2019","journal-title":"Ther Adv Med Oncol June"}],"container-title":["Journal of Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278239122001483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278239122001483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T17:06:09Z","timestamp":1759511169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278239122001483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":248,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0278239122001483"],"URL":"https:\/\/doi.org\/10.1016\/j.joms.2022.02.008","relation":{},"ISSN":["0278-2391"],"issn-type":[{"value":"0278-2391","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"American Association of Oral and Maxillofacial Surgeons\u2019 Position Paper on Medication-Related Osteonecrosis of the Jaws\u20142022 Update","name":"articletitle","label":"Article Title"},{"value":"Journal of Oral and Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joms.2022.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American Association of Oral and Maxillofacial Surgeons","name":"copyright","label":"Copyright"}]}}